NCM · Financial Statements
Alaunos Therapeutics, Inc. (TCRT) Financial Statements
$0.79
NCM: TCRT
Market Cap $1.93M
Overview Financials Dividend Alaunos Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-4.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $3.0M $0 $0 $0 Operating Profit $-78.0M $-35.0M $-34.0M $-5.0M $-4.0M Net Profit $-79.0M $-38.0M $-35.0M $-5.0M $-4.0M EPS $-53.80 $-25.97 $-21.97 $-2.92 $-2.20 Op Margin -19484.7% -1201.4% -685340.0% -48120.0% -84500.0%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $95.0M $65.0M $8.0M $3.0M $3.0M Total Liabilities $37.0M $26.0M $2.0M $1.0M $1.0M Cash $76.0M $39.0M $6.0M $1.0M $1.0M Borrowings $30.0M $20.0M $0 $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-61.0M $-29.0M $-30.0M $-5.0M $-3.0M Investing Cash Flow $-7.0M $0 $1.0M $0 $0 Financing Cash Flow $1.0M $0 $0 $0 $0 Net Cash Flow $-39.0M $-23.0M $-47.0M $-5.0M $0 Free Cash Flow $-65.0M $-29.0M $-30.0M $-5.0M $-3.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.02 EV / EBITDA -0.47 FCF Yield -141.07% Quick Ratio 0.77 Interest Coverage 0.00 Return 1Y -36.98% Return 3Y -96.98% Return 5Y -99.40%
Screens featuring this stock